JP2019505554A5 - - Google Patents

Download PDF

Info

Publication number
JP2019505554A5
JP2019505554A5 JP2018543637A JP2018543637A JP2019505554A5 JP 2019505554 A5 JP2019505554 A5 JP 2019505554A5 JP 2018543637 A JP2018543637 A JP 2018543637A JP 2018543637 A JP2018543637 A JP 2018543637A JP 2019505554 A5 JP2019505554 A5 JP 2019505554A5
Authority
JP
Japan
Prior art keywords
vaccine
antagonist
infection
dose
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018543637A
Other languages
English (en)
Japanese (ja)
Other versions
JP7597500B2 (ja
JP2019505554A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/018487 external-priority patent/WO2017143270A1/en
Publication of JP2019505554A publication Critical patent/JP2019505554A/ja
Publication of JP2019505554A5 publication Critical patent/JP2019505554A5/ja
Priority to JP2022152120A priority Critical patent/JP7813209B2/ja
Priority to JP2024087570A priority patent/JP2024112987A/ja
Application granted granted Critical
Publication of JP7597500B2 publication Critical patent/JP7597500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018543637A 2016-02-19 2017-02-17 Il-4rアンタゴニストを投与することによるワクチンの有効性を増強する方法 Active JP7597500B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022152120A JP7813209B2 (ja) 2016-02-19 2022-09-26 Il-4rアンタゴニストを投与することによるワクチンの有効性を増強する方法
JP2024087570A JP2024112987A (ja) 2016-02-19 2024-05-30 Il-4rアンタゴニストを投与することによるワクチンの有効性を増強する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662297257P 2016-02-19 2016-02-19
US62/297,257 2016-02-19
US201662409936P 2016-10-19 2016-10-19
US62/409,936 2016-10-19
PCT/US2017/018487 WO2017143270A1 (en) 2016-02-19 2017-02-17 Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022152120A Division JP7813209B2 (ja) 2016-02-19 2022-09-26 Il-4rアンタゴニストを投与することによるワクチンの有効性を増強する方法

Publications (3)

Publication Number Publication Date
JP2019505554A JP2019505554A (ja) 2019-02-28
JP2019505554A5 true JP2019505554A5 (cg-RX-API-DMAC7.html) 2020-03-26
JP7597500B2 JP7597500B2 (ja) 2024-12-10

Family

ID=58192407

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543637A Active JP7597500B2 (ja) 2016-02-19 2017-02-17 Il-4rアンタゴニストを投与することによるワクチンの有効性を増強する方法
JP2022152120A Active JP7813209B2 (ja) 2016-02-19 2022-09-26 Il-4rアンタゴニストを投与することによるワクチンの有効性を増強する方法
JP2024087570A Abandoned JP2024112987A (ja) 2016-02-19 2024-05-30 Il-4rアンタゴニストを投与することによるワクチンの有効性を増強する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022152120A Active JP7813209B2 (ja) 2016-02-19 2022-09-26 Il-4rアンタゴニストを投与することによるワクチンの有効性を増強する方法
JP2024087570A Abandoned JP2024112987A (ja) 2016-02-19 2024-05-30 Il-4rアンタゴニストを投与することによるワクチンの有効性を増強する方法

Country Status (17)

Country Link
US (3) US10314904B2 (cg-RX-API-DMAC7.html)
EP (2) EP3416685B1 (cg-RX-API-DMAC7.html)
JP (3) JP7597500B2 (cg-RX-API-DMAC7.html)
KR (1) KR102868264B1 (cg-RX-API-DMAC7.html)
CN (1) CN109069625A (cg-RX-API-DMAC7.html)
AU (2) AU2017220184B2 (cg-RX-API-DMAC7.html)
CA (1) CA3014202A1 (cg-RX-API-DMAC7.html)
ES (1) ES2983475T3 (cg-RX-API-DMAC7.html)
HU (1) HUE067673T2 (cg-RX-API-DMAC7.html)
IL (1) IL261025A (cg-RX-API-DMAC7.html)
MA (1) MA44238B1 (cg-RX-API-DMAC7.html)
MX (2) MX2018009990A (cg-RX-API-DMAC7.html)
PL (1) PL3416685T3 (cg-RX-API-DMAC7.html)
PT (1) PT3416685T (cg-RX-API-DMAC7.html)
RU (1) RU2753869C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017143270A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805295B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
EP3454878A4 (en) * 2016-05-10 2020-07-29 Hennepin Healthcare Research Institute CYTOKINE IMMUNOMODULATORS AND SIGNALING METHODS
KR102872485B1 (ko) * 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
US11034768B2 (en) 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
MA55204A (fr) * 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CA3161037A1 (en) 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
KR20220158821A (ko) * 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
WO2023004420A1 (en) * 2021-07-22 2023-01-26 Icahn School Of Medicine At Mount Sinai Dual-blockade of il-4 signaling and immune checkpoint proteins for treating cancer
US20230167171A1 (en) * 2021-08-23 2023-06-01 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN118717989A (zh) * 2024-05-27 2024-10-01 中国人民解放军军事科学院军事医学研究院 Il-4r拮抗剂在制备预防和/或治疗流感病毒感染的药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
AU2002360278A1 (en) 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
GB0217920D0 (en) * 2002-04-23 2002-09-11 Aventis Pharm Prod Inc Interleukin-4 Gene Expression inhibitors
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX2010006735A (es) 2007-12-21 2010-09-30 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
EP2414520A2 (en) 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
HK1203358A1 (en) * 2012-06-05 2015-10-30 The Australian National University Vaccination with interleukin-4 antagonists
CN118286417A (zh) * 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
RS59354B1 (sr) * 2013-06-21 2019-10-31 Sanofi Biotechnology Postupci lečenja nosne polipoze davanjem il-4r antagonista
KR20190062142A (ko) * 2017-11-28 2019-06-05 (주)비티엔 면역 증강 활성을 가지는 아미노산 미네랄 복합체 및 이를 포함하는 식품, 약학 또는 사료용 조성물
US20210361700A1 (en) * 2020-05-22 2021-11-25 Trustees Of Tufts College Nutritional supplement to combat covid-19 and aid vaccination

Similar Documents

Publication Publication Date Title
JP7813209B2 (ja) Il-4rアンタゴニストを投与することによるワクチンの有効性を増強する方法
Wagner et al. Vaccines to prevent infectious diseases in the older population: immunological challenges and future perspectives
US10406220B2 (en) Pneumococcal dosing regimen
Plotkin et al. The development of vaccines: how the past led to the future
Locht Live pertussis vaccines: will they protect against carriage and spread of pertussis?
Moore Developing vaccines to combat human diseases: a history
Moylett et al. 29. Immunization
Hay What you need to know
Ottolini Current and future use of vaccines for viral and bacterial respiratory tract infections
Backx et al. Immunization
Weinberger Vaccines and vaccination strategies for older adults
AbdelAllah et al. A combined inactivated cholera and hepatitis A vaccine-induced potent protective immunity in a mouse model
HK40117172A (en) Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
Mishra 43 Recent Advances for Immunotherapies Against Infectious Disease
Yaragudi et al. Application of Inhaled Biologics as Vaccines, Part 4
CN117562989A (zh) 用疫苗控制感染性疾病的方法
Raya et al. 153. The Effect of Timing of Tetanus–Diphtheria and Pertussis Vaccine Administration in Pregnancy on The Avidity of Pertussis Antibodies
Miranda Early Childhood Vaccination Schedules in European Union Countries: A Review
MOON Pertussis Booster Protects Teens Beyond 5 Years
HK40001760A (en) Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
HK40001760B (en) Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
Bhat et al. Adolescent Vaccines